ATR and neoplasm: Preclinical observations in vivo suggested that ATR inhibitors, as single agents, can reduce tumor growth in mice,14 15 especially when tumors harbor defects in the DNA damage response.16 17 Hardaker et al evaluated the impact of ceralasertib (an ATR/ATM inhibitor, AZD6738) in syngeneic mouse models of cancer.